Esketamine nasal spray for treatment-resistant depression

  • Technology appraisal guidance
  • TA854
  • Published: 
Download guidance (PDF)

4 Recommendations for research

4.1 Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36.

4.2 Further research is recommended in the wider clinical area of depression on:

  • how clinical data from regulatory trials in depression could appropriately be used in health technology assessment and decision modelling

  • the natural history and long-term course of treatment-resistant depression and health-related quality of life in the long-term

  • characterising the healthcare resource use of people with depression, including exploring which people use services like hospitals and crisis resolution home teams.